Tiziana H1 Loss Widens to $12.4M; Going-Concern Doubt With $3.9M Cash
TLSA sits 38% above its 52-week low of $0.762.
Summary
Tiziana reported a $12.4M first-half loss with only $3.9M of cash and warned of material going-concern doubt unless it raises capital, while the INFORM-MS Phase 2a data readout remains on track for Q4 2026.
Key Events · Earnings and Guidance · TLSA
-
H1 Loss Widens, Cash Dwindles
Total comprehensive loss of $12.4M for the six months to June 30, 2026, versus $5.3M a year earlier. Cash was $3.2M at June 30 and $3.9M as of October 16, 2026.
-
Going-Concern Warning Disclosed
Directors state the company will not be able to meet its liabilities as they fall due within the next 12 months unless it secures sufficient capital, citing a material uncertainty over going concern.
-
Equity Turns Negative
Equity attributable to owners fell to -$2.7M from $52k at December 31, 2025, with accounts payable and accrued expenses up to $13.1M from $10.5M.
-
Warrants Extended to January 2027
The 7,040,000 warrants issued in January 2026 at a $1.50 exercise price were extended six months to January 16, 2027, a post-balance-sheet event.
Analysis · TLSA · Life Sciences
Tiziana's first-half loss more than doubled to $12.4M, and cash stood at just $3.2M at June 30 and $3.9M as of today. Management states plainly that, absent new capital, the company will not be able to meet its liabilities as they fall due within the next 12 months — a material going-concern uncertainty. Shareholders' equity has turned negative (-$2.7M), so the next raise will be dilutive at a $1.05 share price. The offsetting asset is clinical: the INFORM-MS Phase 2a top-line readout is due in Q4 2026, with Alzheimer's and MSA data to follow, and the January 2026 warrants (7.04M at $1.50) were extended to January 2027 rather than allowed to lapse. The company's survival now hinges on financing before that data arrives.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 977 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.7M. The 52-week trading range was $0.76 to $2.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.